Charles River Laboratories International, Inc. (CRL) stock
Close on Nov 12, 2026Market cap $16.27BP/E 401.0Yield –
Charles River Laboratories International, Inc. saw revenue fall 1.2% to $3.98B over the twelve months to Sep 26, 2026. Operating income rose 12.8% to $158.98M, moving the operating margin from 3.5% to 4.0%. Free cash flow was $399.63M, down 26.5% from a year earlier. At the latest close the market valued the company at $16.27B, 401.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 26, 2026
Valuation
- Market cap
- $16.27B
- P/E ratio
- 401.0
- Price to sales
- 4.09
- Price to book
- 5.04
- Dividend yield
- –
- Free cash flow yield
- 2.46%
Fundamentals
- Revenue
- $3.98B
- Net income
- $40.19M
- EPS, diluted
- $0.85
- Free cash flow
- $399.63M
- Book value per share
- $66.42
- Diluted shares
- 49M
Trading
- Next earnings
- Jan 12, 2027 (estimated, before the open)
- Previous close
- $342.69
- Open
- $335.66
- Day's range
- $326.29 – $342.83
- Volume
- 902,120
- Average volume (20 days)
- 1,294,315
- Index membership
- S&P 500 (since Jun 2021), Russell 1000, Russell 3000
- Beta (5 years)
- 1.19
- 52-week range
- $146.19 – $379.63
- RSI (14 days)
- 53.6
- Volatility (1 year)
- 47.6%
- Relative volume
- 0.89×
- WACC
- 10.0%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRL | S&P 500 | Difference | CRL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.9% | -2.7% | +15.6 pts | ||
| 3 months | +19.8% | -1.7% | +21.6 pts | ||
| Year to date | +70.8% | +11.9% | +59.0 pts | ||
| 1 year | +98.7% | +12.0% | +86.7 pts | ||
| 3 years | +98.2% | +78.2% | +20.0 pts | +25.6% | +21.2% |
| 5 years | -11.7% | +73.2% | −84.9 pts | -2.5% | +11.6% |
| 10 years | +356.7% | +309.6% | +47.0 pts | +16.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Charles River Laboratories International filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Results
- Results
About Charles River Laboratories International
Services-Commercial Physical & Biological Research
Charles River Laboratories International, Inc. is an early-stage drug development partner offering research models and non-clinical development services. The company organizes its operations across three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Its core offerings include purpose-bred rodents and larger research models, genetically engineered model creation, diagnostic testing, and cellular materials for research and therapies. It also delivers integrated drug discovery, bioanalytical support, safety pharmacology, specialized toxicology, pathology evaluations, and quality control testing such as endotoxin and microbial detection. The company serves global pharmaceutical and biotechnology corporations, academic institutions, contract research organizations, hospitals, and government agencies, along with chemical, consumer product, and medical device manufacturers.
Company profile, executives and historyCharles River Laboratories International stock: common questions
What is Charles River Laboratories International's stock price?
CRL closed at $340.81 on Nov 12, 2026, down 0.55% on the day. Over the past 52 weeks it traded between $146.19 and $379.63.
What is Charles River Laboratories International's market cap?
Charles River Laboratories International was worth $16.27B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CRL's P/E ratio?
CRL trades at 401.0 times earnings, based on diluted earnings per share of $0.85 over the twelve months to Sep 26, 2026.
How much revenue does Charles River Laboratories International make?
Charles River Laboratories International reported revenue of $3.98B for the twelve months to Sep 26, 2026, down 1.2% from a year earlier.
Does Charles River Laboratories International pay a dividend?
No. Charles River Laboratories International has not paid a cash dividend over the last twelve months.
When does Charles River Laboratories International report earnings next?
Charles River Laboratories International is expected to report Q4 FY2026 results on Jan 12, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CRL stock performed over the past year?
Including dividends, CRL returned +98.7% over the past year, against +12.0% for the S&P 500.
How many CRL shares are sold short?
3M shares were sold short at the latest FINRA report, 6.33% of the float, or 2.2 days of average trading volume.
Who are Charles River Laboratories International's competitors?
Companies most similar to Charles River Laboratories International by business, industry and size include MEDP, ICLR, INCY, IQV, ULS.
See a number that looks wrong?